DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
CRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sell
The first attempts to use a groundbreaking gene-editing technology in people will likely target patients with sickle cell disease, a crippling inherited disorder that in the U.S. predominantly strikes African-Americans.
That should be welcome news, after decades of sickle cell patients being neglected by the health care system, scientists, and drug companies. But the long and ugly history of unethical experimentation and mistreatment of black patients could make recruiting volunteers to try largely untested CRISPR therapies a tough sell.
“You can’t expect this population is just going to stick out their arm for an IV,” said Mary Brown, who heads the Sickle Cell Disease Foundation of California and has worked with patients for four decades. “There’s a lot of education that needs to be done. I don’t want to say hand-holding, but that’s what it is.”
news & eventsNew Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell AnemiaResearchers at New York’s Weill Cornel...
videos & visualsSCDAA Gene Therapy Town Hall – Webinarhttps://www.youtube.com/watch?v=J77Gq9yI...
education & researchClinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA u...Advances in allogeneic hematopoietic cel...
education & researchGuidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British society for ha...Sickle cell disease (SCD) is a generic t...
news & eventsGenetic Treatments for Sickle CellFor decades physicians have known that a...
news & eventsCalifornia Institute For Regenerative Medicine Awards City Of Hope $5.74 Million For Severe Sickle Cell Disease Clin...The California Institute for Regenerativ...
news & eventsStatement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.